Glutathione (GSH) is a tripeptide comprising three amino acids—cysteine, glycine, and glutamic acid—that functions as the body's primary endogenous antioxidant. It plays a critical role in neutralizing free radicals, supporting liver detoxification, and maintaining cellular redox balance [1]. While the body synthesizes its own glutathione, depletion can occur due to aging, chronic illness, and environmental stress. Supplementation aims to restore these levels, but standard oral powders have historically suffered from poor bioavailability, leading to the development of liposomal forms and alternative precursor strategies (like N-Acetyl Cysteine).
Glutathione is generally well-tolerated in oral and liposomal forms. Intravenous (IV) glutathione requires medical supervision due to risks of anaphylaxis and hepatotoxicity. Asthmatic patients should avoid inhaled glutathione as it may trigger bronchospasm.
Liposomal glutathione and sustained oral glutathione dosing (up to 6 months) effectively increase body stores of the antioxidant. It shows moderate evidence for supporting liver function and oxidative stress markers, but evidence for popular cosmetic uses (like skin lightening) remains controversial and carries safety warnings when used intravenously.
Glutathione functions as a direct scavenger of reactive oxygen species (ROS) and is crucial for phase II liver detoxification, where it binds to fat-soluble toxins to make them water-soluble for excretion.
Clinical research has investigated glutathione for several specific health outcomes:
For decades, standard oral glutathione was dismissed by researchers because it is rapidly broken down by peptidases in the gastrointestinal tract before reaching the bloodstream [7]. However, recent data provides a more nuanced picture:
Glutathione exists in two states: reduced (GSH) and oxidized (GSSG). The ratio of GSH to GSSG is a primary indicator of cellular oxidative stress.
As an antioxidant, the sulfhydryl (thiol) group on the cysteine moiety of GSH donates a reducing equivalent (an electron) to unstable reactive oxygen species (such as hydrogen peroxide or lipid peroxides). In the process, GSH becomes reactive and binds with another GSH molecule to form oxidized glutathione (GSSG). The enzyme glutathione reductase then recycles GSSG back to GSH using NADPH. In addition to ROS scavenging, glutathione conjugates with xenobiotics and heavy metals via the enzyme glutathione S-transferase, facilitating their excretion via bile and urine [1:2].
| Outcome / Metric | Evidence Quality (GRADE) | Efficacy | Notes | Reference |
|---|---|---|---|---|
| Increased Blood & Tissue GSH Levels | High | Significant | 250–1,000 mg daily oral dosing over 6 months increased stores by 17–35%. Liposomal forms show even more rapid uptake. | [3:2][2:3] |
| Reduction in Oxidative Stress Biomarkers | Moderate | Moderate | Decreased lipid peroxidation and improved redox balance in several clinical trials, though some short-term oral studies failed to show changes. | [3:3][7:1] |
| Improvement in NAFLD Markers | Moderate | Moderate | Reduces liver enzymes (ALT/AST) and provides therapeutic potential in managing fatty liver progression. | [1:3] |
| Immune Marker Elevation | Moderate | Moderate | Liposomal administration enhanced immune markers (NK cell activity, lymphocyte proliferation) in human trials. | [4:1][2:4] |
| Skin Lightening / Melanin Reduction | Low | Mild | Oral and topical forms show modest effects on melanin indices in some trials. IV use lacks rigorous safety data and is strongly discouraged. | [5:2][6:1] |
Glutathione is a naturally occurring peptide, and oral supplementation is widely regarded as safe (GRAS).
While both aim to increase cellular glutathione, they function differently:
Santacroce, G., Gentile, A., Soriano, S., Novelli, A., Lenti, M. V., & Di Sabatino, A. (2023). Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease. Frontiers in Medicine. https://pubmed.ncbi.nlm.nih.gov/37035339/ ↩︎ ↩︎ ↩︎ ↩︎
Sinha, R., Sinha, I., & Calcagnotto, A. (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition, 72(1), 105-111. https://pubmed.ncbi.nlm.nih.gov/28853742/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Richie, J. P. Jr, Nichenametla, S., Neidig, W., Calcagnotto, A., Haley, J. S., Schell, T. D., & Muscat, J. E. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition, 54(2), 251-263. https://pubmed.ncbi.nlm.nih.gov/24791752/ ↩︎ ↩︎ ↩︎ ↩︎
To, K., Cao, R., & Yegiazaryan, A. (2021). Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes. Frontiers in Cellular and Infection Microbiology. https://pubmed.ncbi.nlm.nih.gov/34150674/ ↩︎ ↩︎
Alzahrani, T. F., Alotaibi, S. M., & Alzahrani, A. A. (2025). Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review. Cureus. https://pubmed.ncbi.nlm.nih.gov/40013212/ ↩︎ ↩︎ ↩︎ ↩︎
Handog, E. B., Datuin, M. S., & Singzon, I. A. (2016). An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. International Journal of Dermatology, 55(2), 153-157. https://pubmed.ncbi.nlm.nih.gov/26148180/ ↩︎ ↩︎
Allen, J., & Bradley, R. D. (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine, 17(9), 827-833. https://pubmed.ncbi.nlm.nih.gov/21875351/ ↩︎ ↩︎
Drugs.com. (2024). Glutathione Uses, Benefits & Dosage. https://www.drugs.com/npp/glutathione.html ↩︎ ↩︎